Reviewing Aardvark Therapeutics (AARD) and Its Rivals

Aardvark Therapeutics (NASDAQ:AARD) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its rivals? We will compare Aardvark Therapeutics to related businesses based on the strength of its profitability, valuation, analyst recommendations, dividends, earnings, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Aardvark Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	1	0	10	1	2.92
Aardvark Therapeutics Competitors	6624	12460	38211	1213	2.58

Aardvark Therapeutics currently has a consensus price target of $32.70, suggesting a potential upside of 129.31%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 51.51%. Given Aardvark Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than its rivals.

Institutional & Insider Ownership

51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.5% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Aardvark Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-54.90%	-37.86%
Aardvark Therapeutics Competitors	-906.16%	-572.54%	-29.84%

Valuation and Earnings

This table compares Aardvark Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aardvark Therapeutics	N/A	-$20.59 million	-6.73
Aardvark Therapeutics Competitors	$968.47 million	-$41.36 million	9.88

Aardvark Therapeutics’ rivals have higher revenue, but lower earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Aardvark Therapeutics beats its rivals on 7 of the 12 factors compared.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.